Author Question: A patient is using psyllium hydrophilic mucilloid (Metamucil) to promote evacuation of stool. What ... (Read 162 times)

Pineappleeh · **on:** Jul 23, 2018

A patient is using psyllium hydrophilic mucilloid (Metamucil) to promote evacuation of stool. What is the action of this medication?

A) It reduces the surface tension of bowel contents.
B) It irritates the intestinal mucosa, thus increasing intestinal motility.
C) It increases mass and water content of stool, promoting evacuation.
D) It creates a barrier between the colon wall and feces.

Question 2

A 55-year-old man has been diagnosed with coronary artery disease and begun antiplatelet therapy. The man has asked the nurse why he is not taking a blood thinner like warfarin.

What is the most likely rationale for the clinician's use of an antiplatelet agent rather than an anticoagulant? A) Antiplatelet agents do not require the man to undergo frequent blood work; anticoagulants require constant blood work to ensure safety.
B) Antiplatelet agents are more effective against arterial thrombosis; anticoagulants are more effective against venous thrombosis.
C) Antiplatelet agents are most effective in large vessels; anticoagulants are most effective in the small vessels of the peripheral circulation.
D) Antiplatelet agents have fewer adverse effects than anticoagulants.

zacnyjessica · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

C
Feedback:
Bulk-forming laxatives increase mass and water content of the stool, promoting evacuation. Bulk-forming laxatives do not reduce surface tension of bowel contents. Bulk-forming laxatives do not irritate the intestinal mucosa to increase intestinal motility. Bulk-forming laxatives do not create a barrier between the colon wall and feces.

Answer to Question 2

B
Feedback:
Anticoagulants are more effective in preventing venous thrombosis than arterial thrombosis. Antiplatelet drugs are used to prevent arterial thrombosis. CAD has an arterial rather than venous etiology. The rationale for the use of antiplatelet agents in CAD is not likely related to the need for blood work or the presence of adverse effects.